ALKS
ALKS
NASDAQ · Biotechnology

Alkermes Plc

$28.40
+0.69 (+2.49%)
As of Mar 24, 9:52 PM ET ·
Financial Highlights (FY 2026)
Revenue
1.54B
Net Income
363.64M
Gross Margin
84.2%
Profit Margin
23.6%
Rev Growth
+9.9%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 84.2% 84.2% 61.4% 61.4%
Operating Margin 27.0% 24.3% 15.6% 13.8%
Profit Margin 23.6% 22.4% 14.1% 13.4%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 1.54B 1.40B 1.89B 1.59B
Gross Profit 1.30B 1.18B 1.16B 979.55M
Operating Income 416.63M 341.22M 295.17M 220.02M
Net Income 363.64M 297.82M 267.01M 214.03M
Gross Margin 84.2% 84.2% 61.4% 61.4%
Operating Margin 27.0% 24.3% 15.6% 13.8%
Profit Margin 23.6% 22.4% 14.1% 13.4%
Rev Growth +9.9% +9.9% +6.3% -8.7%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 803.02M 723.95M
Total Equity 3.18B 3.20B
D/E Ratio 0.25 0.23
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA 427.43M 369.52M 438.15M 351.76M
Free Cash Flow 233.31M 225.75M